Search Results - "Vazquez Blanco, S"

1ISG-030 Economic impact of biological medicines on a third level hospital by Fortes González, S, Vazquez Blanco, S, Herrero Poch, L, De Miguel Bouzas, JC, Castro Dominguez, JM, Villamayor Blanco, L

“…Background and importanceHigh costs of biological medicines (BM) are a financial issue for hospitals. The arrival of biosimilar drugs (BS) improved their…”
Get full text

PKP-032 Pharmacokinetically guided dose adjustment of digoxin in institutionalised patients by Gonzalez, MS Fortes, Vieitez, A Ballester, Poch, L Herrero, Blanco, S Vázquez, Crespo-Diz, C

“…BackgroundDeterioration in renal function occurs with ageing and can affect drug pharmacokinetics, decreasing elimination. Furthermore, the narrow therapeutic…”
Get full text

PP-038 Design, pharmaceutical validation and microbiological control of aflecainide syrup for paediatric use by Mayo, ME García, Freire, L González, Pousa, MC Dávila, Blanco, S Vázquez, Chenlo, C Soneira, Diz, C Crespo

“…BackgroundExtemporaneous solutions using pure active ingredients instead of commercially available drugs are a safer option due to their lack of excipients…”
Get full text

CP-203 Safety of paclitaxel albumin bound nanoparticles plus gemcitabina in metastasic pancreatic adenocarcinoma by Blanco, S Vázquez, González, MS Fortes, Ribeiro, MF Fernández, Mayo, ME Garcia, Freire, L González, Fernández, R Olivera, Crespo-Diz, C

“…BackgroundPaclitaxel albumin bound nanoparticles (nab-Paclitaxel) is indicated for the treatment of metastasic pancreatic adenocarcinoma (MPA). In clinical…”
Get full text

5PSQ-061 Alemtuzumab for relapsing–remitting multiple sclerosis: effectiveness and safety by Vázquez Blanco, S, Fortes González, S, Herrero Poch, L, De Miguel Bouzas, JC, Castro Domínguez, JM, Villamayor Blanco, L

“…Background and importanceAlemtuzumab is a humanised monoclonal antibody that selectively targets CD52, indicated in adult patients with relapsing–remitting…”
Get full text